MA-WHOOP
WHOOP, the human performance company, today announced the expansion of its global footprint, now shipping to 56 markets worldwide, with more launches ahead. Additionally, the WHOOP app is now available in Italian and Spanish (Latin America), as well as English, French, and German. To support continued growth and momentum, WHOOP named new leaders to its C-suite to deliver on the WHOOP mission of helping people achieve their goals, by providing best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, strain, and health. To help everyone start their journey, WHOOP is currently offering a one-month free trial that can be accessed on WHOOP.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429085870/en/
WHOOP announces significant global expansion, appoints new senior leadership. Continues "Free Trials," making it the only wearable to offer "Try Before You Buy." (Photo: Business Wire)
WHOOP Global Expansion
With a commitment to serving its global community to unlock their potential, WHOOP has expanded its reach to several key markets and regions, where there’s been rising consumer demand for and adoption of the brand. Consumers in Qatar, Saudi Arabia, Kuwait, Bahrain, Hong Kong, Israel, Korea, and Taiwan can now purchase WHOOP directly and the brand will ship to each of these markets, creating a seamless experience for its members.
The Gulf is a key region for the brand’s growth. In fact, their digital health market is expected to witness healthy, double-digit growth by 2027, according to Medi-Tech Insights. As a world class health and performance monitor, WHOOP provides coaching to improve overall well-being and foster behavior change.
To support global expansion, the WHOOP app is now available in Italian and Latin American Spanish to complement its existing languages: English, French and German, with additional language rollouts to come. This expansion ensures that WHOOP members worldwide can access the full suite of content and features in their native language.
“WHOOP is experiencing remarkable growth and momentum, particularly in new markets around the world. We’re excited to open these new markets and provide over 125 million people with access to WHOOP,” said Will Ahmed, Founder and CEO of WHOOP. “This market growth and the launch of Spanish and Italian in the WHOOP app is just the start of our international expansion. Our teams, including those led by three of our newest C-suite leaders, are working every day to unlock new markets and help introduce new members to the power of our WHOOP membership.”
New Executive Leadership at WHOOP
To spearhead continued growth and global expansion, WHOOP has appointed new leaders to its executive team:
- Ed Baker joins WHOOP as Chief Growth Officer, following the acquisition of Baker's previous company, AnyQuestion. Before that, Baker led growth teams at Facebook and Uber during periods of extraordinary growth. He has also served on the WHOOP Board of Directors for nearly five years. Baker will lead efforts to fuel the next phase of hyper-growth at WHOOP.
- Michener Chandlee is now Chief Financial Officer at WHOOP, leveraging his extensive financial expertise to drive strategic financial planning and operational excellence. Prior to WHOOP, Chandlee was the CFO of Fanatics and also spent nearly 20 years at Nike in various leadership roles, including Chief Risk Officer and CFO of Nike’s Global Marketplace.
- John Sullivan has been promoted to Chief Marketing Officer, bringing his wealth of experience in marketing strategy and brand development to further elevate the presence of WHOOP in the global marketplace. Sullivan has worked at WHOOP for more than seven years during which he’s developed the direct-to-consumer business at WHOOP, overseeing all marketing functions of Brand, Commercial, Lifecycle, Business Development and Accessories and Apparel. Prior to WHOOP, he held positions in marketing at Tracksmith, Puma and Monitor Group, a strategy consulting firm.
To learn more and discover how WHOOP helps its members unlock their performance, go to www.whoop.com. To make it even more convenient than ever before to access WHOOP, it is available for purchase on Amazon.com, as well as at Best Buy and Dick’s Sporting Goods.
ABOUT WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. WHOOP Unite is a comprehensive solution dedicated to supporting organizations across a wide range of industries with coaching, organizational insights, and health programs. Studies show WHOOP can positively change behavior, increase sleep, and improve physiological biomarkers. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. The latest round of financing made WHOOP the world's most valuable standalone wearables company. Visit WHOOP.com for more information and connect with WHOOP on Instagram, Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429085870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
